LifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedMW
Milky Way Investments
Activity from announced rounds
Activity in this selectionUnited States · Oct 4, 2026 · Jul 7, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $263M 1 disclosed · full round size, not this investor’s share